Article Text


Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS): a study protocol for a double-blind, randomised, placebo-controlled, proof-of-concept study
  1. Per Ederoth1,
  2. Edgars Grins1,
  3. Alain Dardashti1,
  4. Björn Brondén1,
  5. Carsten Metzsch1,
  6. André Erdling1,
  7. Shahab Nozohoor2,
  8. Arash Mokhtari2,
  9. Magnus J Hansson3,
  10. Eskil Elmér3,
  11. Lars Algotsson1,
  12. Stefan Jovinge4,5,
  13. Henrik Bjursten2
  1. 1Department of Anesthesiology and Intensive Care, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden
  2. 2Department of Cardiothoracic Surgery, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden
  3. 3Department of Mitochondrial Medicine, Clinical Sciences, Lund University, Lund, Sweden
  4. 4Fredrik Meijer Heart and Vascular Institute Spectrum Health, MI US Van Andel Institute, Grand Rapids, Michigan, USA
  5. 5Cardiovascular Institute, Stanford University, Stanford, California, USA
  1. Correspondence to Dr Per Ederoth; per.ederoth{at}


Introduction Acute kidney injury (AKI) after cardiac surgery is common and results in increased morbidity and mortality. One possible mechanism for AKI is ischaemia–reperfusion injury caused by the extracorporeal circulation (ECC), resulting in an opening of the mitochondrial permeability transition pore (mPTP) in the kidneys, which can lead to cell injury or cell death. Ciclosporin may block the opening of mPTP if administered before the ischaemia–reperfusion injury. We hypothesised that ciclosporin given before the start of ECC in cardiac surgery can decrease the degree of AKI.

Methods and analysis Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS) study is an investigator-initiated double-blind, randomised, placebo-controlled, parallel design, single-centre study performed at a tertiary university hospital. The primary objective is to assess the safety and efficacy of ciclosporin to limit the degree of AKI in patients undergoing coronary artery bypass grafting surgery. We aim to evaluate 150 patients with a preoperative estimated glomerular filtration rate of 15–90 mL/min/1.73 m2. Study patients are randomised in a 1:1 ratio to receive study drug 2.5 mg/kg ciclosporin or placebo as an intravenous injection after anaesthesia induction but before start of surgery. The primary end point consists of relative P-cystatin C changes from the preoperative day to postoperative day 3. The primary variable will be tested using an analysis of covariance method. Secondary end points include evaluation of P-creatinine and biomarkers of kidney, heart and brain injury.

Ethics and dissemination The trial is conducted in compliance with the current version of the Declaration of Helsinki and the International Council for Harmonisation (ICH) Good Clinical Practice guidelines E6 (R1) and was approved by the Regional Ethical Review Board, Lund and the Swedish Medical Products Agency (MPA). Written and oral informed consent is obtained before enrolment into the study.

Trial registration number NCT02397213; Pre-results.

Statistics from

Strengths and limitations of this study

  • Randomised, controlled, double-blind, prospective clinical trial.

  • Two Drug Safety Monitoring Board (DSMB) meetings have recommended that the study be continued.

  • Strictly standardised study population.

  • Possible selection bias because all possible patients may not be entered in the study.


Acute kidney injury (AKI) is a common complication after cardiac surgery, with an incidence between 5% and 40% depending on the definition.1–5 A decreased renal function after cardiac surgery is associated with decreased long-term survival.2–5 Despite trials investigating several pharmaceutical agents,6–9 no effective prophylactic treatments have so far been found.

Cardiac surgery with extracorporeal circulation (ECC) may result in renal ischaemia–reperfusion injury, especially in the poorly oxygenated and metabolic active outer medulla. Thus, ECC-induced renal ischaemia–reperfusion injury is claimed to play a role in the resulting AKI.10

The proposed mechanism for AKI induced by renal ischaemia–reperfusion injury is opening of channels called the mitochondrial permeability transition pore (mPTP) during reperfusion. This can amplify or accelerate cell death, resulting in reperfusion-induced necrosis.11–17

The inner mitochondrial membrane is normally impermeable to most solutes, enabling efficient ATP production through oxidative phosphorylation. Under conditions of elevated Ca2+ levels and oxidative stress triggered by reperfusion after ischaemia, the mPTP in the inner mitochondrial membrane opens. On the mPTP opening, energy production is immediately halted and molecules smaller than ∼1500 Da equilibrate over the membrane. The osmotic force of matrix proteins results in matrix swelling, leading to rupture of the outer membrane and release into the cytosol of proapoptotic factors such as cytochrome C, further pushing the cell towards death.13 ,18 ,19

Cyclophilin-D is a key regulator of the mPTP, which has been confirmed in several independent cyclophilin-D knock-out studies. Ca2+ causes a conformational change in the mPTP from a closed to an open state.20–22 The opening of the mPTP can be inhibited pharmacologically by the immunosuppressive agent ciclosporin via inhibition of cyclophilin-D,23 ,24 and several reports in animals have indicated that it may limit ischaemia–reperfusion injury in various organs, including the kidneys.25–29 A cyclophilin-D activated mPTP has also been demonstrated in human mitochondria.30–33

Further, there are a number of animal studies showing cytoprotective preconditioning, antinecrotic and also antiapoptotic effects of ciclosporin against ischaemia–reperfusion injury in the kidneys.34–38 Importantly, ciclosporin has been administered before the kidney is exposed to ischaemia and subsequent reperfusion in these studies.

To the best of our knowledge, no clinical studies with the specific aim of investigating if ciclosporin has renoprotective effects if administered before the ischaemia–reperfusion episode have previously been performed. In contrast, ciclosporin is known to cause renal failure following high and/or long-term exposure. However, this side effect is caused by other mechanisms, discussed under ‘Safety considerations’ section.


On the basis of the aforementioned, we raised the hypothesis that ciclosporin, administered as a single intravenous bolus dose preoperatively in cardiac surgery with ECC, will reduce the level of renal dysfunction associated with this type of surgery.

Methods and analysis

Study design

We designed an investigator-initiated, clinical, double-blind, randomised, placebo-controlled, parallel design clinical trial based on a single centre aiming to detect if there is a role for ciclosporin in renal protection. Study patients will be randomised in a 1:1 ratio. We plan to have a total of 150 consecutive evaluable study patients with ∼75 patients in each arm. Approximately 170 patients are estimated to be enrolled, in order to have 150 evaluable patients for the two groups.


Day numbering: Day 0 will be the surgery and study drug administration day. Day 1 is the day the study patients are included and is normally the day before surgery and day 1 the first day after surgery, etc. On day 0, the end of ECC is defined as time zero.

Data collection

Efficacy data will be collected on day 1 until, and including, day 4 as long as the patient is present at the hospital. Safety data will be collected from the time for distribution of study drug until, and including, day 4 as long as the patient is present at the hospital. From day 4 until day 30, serious adverse events (SAEs) and serious unexpected adverse reactions (SUSARs) will be reported.

For details, see table 1 and figure 1.

Table 1

Participant timeline

Figure 1

Schematic flow chart of the CiPRICS study. CiPRICS, Ciclosporin to Protect Renal function In Cardiac Surgery; eGFR, estimated glomerular filtration rate; SAE, serious adverse event; SUSAR, serious unexpected adverse reaction.

Study drug

The study drug is CicloMulsion, a 5 mg/mL ready-to-use lipid emulsion of ciclosporin (NeuroVive Pharmaceutical AB, Lund, Sweden) or its matching placebo, given as a single intravenous bolus dose of 0.5 mL/kg. The qualitative composition of CicloMulsion and its placebo only differ in the presence or absence of ciclosporin, so the final emulsions will be visually indistinguishable.

Eligibility criteria

This study will be eligible for patients planned for coronary artery bypass grafting (CABG), a standardised operation including the use of ECC.

Inclusion criteria

  1. The study patient is scheduled for non-emergent (decision to operate more than 1 hour before start of surgery) CABG surgery.

  2. Preoperative cystatin C estimated glomerular filtration rate (eGFR) or the Modification of Diet for Renal Disease (MDRD) eGFR is 15–90 mL/min/1.73/m2. eGFR will be calculated using both creatinine based on the MDRD39 and the cystatin C based formula on the Chronic Kidney Disease Epidemiological collaboration (CKD-EPI).40 The lowest eGFR value will be used as inclusion criteria.

  3. The patient has given his/her written consent to participate.

Exclusion criteria

Patients are excluded if they meet one or more of the following criteria:

  1. The patient has an uncontrolled hypertension.

  2. Hypersensitivity to the active drug or vehicle, including egg protein, soya protein or peanut protein.

  3. The patient is pregnant or is a fertile woman.

  4. The patient has been treated with ciclosporin within 4 weeks prior to the surgery.

  5. The patient has a known ongoing malignancy.

  6. The patient has ongoing immunosuppressive treatment.

  7. The patient has severe hepatic dysfunction.

  8. The patient is treated with dialysis.

  9. The patient has preoperatively ongoing and/or increasing clinical infection with C reactive protein (CRP) levels of >50 mg/L. Clinical signs of infection may or may not be present. Increase in CRP due to signs of cardiac origin,41 according to the investigator, should not be considered as exclusion criteria.

  10. The patient has a severe ongoing viral infection, including HIV, hepatitis C, current or history of hepatitis B.

  11. For non-allowed and restricted ongoing and concomitant medications, see Protocol section 12.2.

  12. The patient is planned for off-pump CABG surgery.

  13. The patient is included in other ongoing clinical trials.

  14. For any other reason, the patient is unsuitable to participate in the study, according to the investigator.

Recruitment and stratification

Potential participants are identified from patients planned for elective CABG and included in a screening log. Patients are checked against the inclusion/exclusion criteria, and thereafter oral and written information is given to the patient. When written informed consent is obtained by an investigator, the patient is enrolled in the study.

At enrolment, the investigator also stratifies the patient to a predefined subgroup with reference to preoperative eGFR (15–59 or 60–90 mL/min/1.73 m2). When several patients fulfil the inclusion criteria, those with preoperative eGFR 15–59 are selected over those with 60–90 mL/min/1.73 m2 with the aim of including ∼50 patients from the group with eGFR 15–59 mL/min/1.73 m2. The reason for this is that preoperative renal function impairment is an important risk factor for developing postoperative AKI,42 and we know that without stratification there will only be a few patients enrolled with eGFR 15–59 mL/min/1.73 m2. Thus, we also investigate if treatment effects are similar in patients with preoperative milder and more severe renal impairment. Also, within each eGFR group, the study drug and placebo will be stratified in a 1:1 ratio. In summary, the stratification will increase the proportion of patients with a higher risk of developing AKI.


For randomisation to study drug or placebo treatment, a blinded randomisation list was pregenerated by a statistician not included in the study group (FoU-centrum Skane, Skane University Hospital, Lund, Sweden), to assign a unique sequential treatment number to each bottle of the study drug/placebo. The unique treatment number was printed on the study medication bottle, where also a sticker for the case report form (CSF) was positioned. The bottles with the study drug/placebo were packed in boxes marked with eGFR 15–59 or 60–90 mL/min/1.73 m2 according to the stratification aforementioned. Study drug/placebo is kept in two separate sets, one set for patients with eGFR 15–59 mL/min/1.73 m2 and one set for patients with eGFR 60–90 mL/min/1.73 m2.

Following completion of the assessments listed above, eligible patients will be allocated to one of the two treatment groups in a 1:1 ratio, to receive either a single intravenous bolus injection of ciclosporin or matching placebo by the following action.

Once the study patient has been admitted to the operation ward, a box with the allocated study drug/placebo is taken by the study nurse and the treatment number from that box and study drug/placebo bottle is attached in the CRF. The allocation to the study drug/placebo following the generated randomisation list will thus take place when the study nurse takes the next study medicine bottle, as described here, and prepares the syringe with the study drug/placebo.

Thus, the study treatment is blinded for all involved staff. Closed envelopes with unblinding information is available at the operating ward in case of emergency situations.


After randomisation, the study drug/placebo will be administered as an intravenous single bolus dose injection, 0.5 mL/kg body weight (corresponding to 2.5 mg/kg ciclosporin), after anaesthetic induction has been performed and the patient is in a stable circulatory state before the surgery starts. The study drug/placebo will be given in a central venous catheter as an injection during 10 min, without concomitant administration of other drugs in this line. Anaesthesia is standardised using propofol, fentanyl and rocuronium. Anaesthetic gas is prohibited medicine in this study.

Sample size calculations

A total of 150–170 patients will be included to obtain a total of 150 evaluable study patients with ∼75 patients in each arm. The relative difference between groups in change from baseline P-cystatin C to the third postoperative day will serve as the primary end point. In a previous study at our department,7 the response within each participant group was normally distributed with an SD of 27%. The primary efficacy analysis will compare the ciclosporin group to placebo at a two-sided 5% level. A sample size equal to 75 in each arm will provide at least 80% power to detect a 13% units (0.5 SD) difference from placebo. The study will continue until the planned number of study patients have finalised the protocol.


Primary end point

  • Relative P-cystatin C change from day 1 to day 3.

Secondary end points

  • Secondary end points to evaluate ciclosporin’s effect on renal function include, but are not limited to, P-cystatin C day 1 versus days 1, 2 and 4, P-cystatin C area under curve day 1 to day 4, P-cystatin C and P-creatinine eGFR according to CKD-EPI, P-creatinine, MDRD eGFR. Biomarker for renal damage based on tissue inhibitor of metalloproteinases-2 (U-TIMP-2) and urine insulin-like growth factor binding protein 7 (U-IGFBP7) levels.43 U-albumin/creatinine. Incidence of AKI according to predefined eGFR stratification (15–59 and 60–90 mL/min/1.73/m2) and Risk, Injury, Failure, Loss and End-stage renal failure (RIFLE) criteria based on P-creatinine and/or eGFR.44

  • To evaluate ciclosporin’s possible effect on myocardial injury,45 plasma creatine kinase isoenzyme MB (P CK MB) and P-troponin T will be measured.

  • Ciclosporin also has a possible cerebral protective effect,46 and therefore S-S100B is evaluated from day 1 throughout day 2.

  • Clinical and procedural secondary variables include ECC time, operation time, respiratory time, blood pressure, temperature, etc.

  • B-ciclosporin will be measured after injection, after end of ECC and on the morning of day 1.

  • In addition, a number of immunological parameters will be measured on an exploratory basis; serum will be screened for cytokines related to the inflammatory cell pattern aiming for tissue aggressive inflammatory reaction (tumour necrosis factor-α, interleukin (IL)-1β, IL-6, IL-7, IL-12, IL-17, interferon-γ), regulatory/immune-suppressive function (IL-2, IL-10), neutrophil activation (IL-8) and tissue-lenient inflammatory responses (IL-2, IL-4, IL-13). Natural killer cells, T-cell populations (Th1, Th2, Th17) as well as B cells will be evaluated as well.


The study is monitored by the clinical research organisation at Skane University Hospital, Lund (FoU-centrum Skane, Skane university hospital, Lund, Sweden). This is an independent in-house Contract Research Organisation (CRO).

Data analysis plan

The statistical analysis plan (SAP) will be signed before database lock. Analyses not described here or in the SAP will be considered exploratory/post hoc analyses.

In general, descriptive statistics will be presented for all efficacy and safety variables, as appropriate. Continuous variables will be summarised by descriptive statistics (sample size (n), mean, SD, minimum, median and maximum values). Categorical data will be summarised in frequency tables showing the number of study patients, frequency and percentage of occurrence.

All statistical tests will be conducted at the two-sided 5% level unless otherwise specified. Where appropriate, model-based point estimates, together with their 95% CIs, will be presented along with the two-sided p value for the test.

The primary comparison will be to investigate difference in P-cystatin C change from baseline to the third postoperative day between ciclosporin and placebo. The treatment difference in the secondary and exploratory end points described earlier will also be tested.

The primary end point, P-cystatin C relative change from baseline to the third postoperative day, will be analysed using analysis of covariance (ANCOVA). The model will include treatment and baseline P-cystatin C as explanatory variables.

Secondary end points will mainly be analysed by using ANCOVA, following the same conventions as in the analysis of the primary end point.

Exploratory analyses will be performed of several quality indices including, for example, time on mechanical ventilator, time on intensive care unit, extent of bleeding, incidence of atrial fibrillation, time on ECC, immunological parameters, etc.

If assumptions for parametric analysis are clearly violated, data transformations or a non-parametric approach will be applied.

Organisation and time line

The study team involves at the moment 10 investigators and 2 research nurses. It is a single-centre study performed in a tertiary hospital (Department of Cardiothoracic Surgery, Anaesthesia and Intensive Care, Skane University Hospital, Lund, Sweden). The first patient was included on 6 April 2015. The last patient is expected to be included during 2016.

Ethics and dissemination


The trial is conducted in compliance with the current version of the Declaration of Helsinki and the ICH Good Clinical Practice guidelines E6 (R1). The trial has been registered under NCT02397213 and EudraCT: 2014-004610-29, Sponsor's Protocol Code Number 2014.001.

Safety considerations

The reporting of adverse events (AE) will begin after the start of study medication and last until the follow-up phone call is made 1 month after day of operation. AEs also include SAE and SUSARs reporting. This is performed according to the Swedish Medical Products Agency’s (MPA) regulations.

AEs, safety blood chemistry (table 1) and clinical data are collected daily including day 4. A telephone call on day 30 will assess and register possible SAE and signs of infection.

Drug Safety Monitoring Board

An independent Drug Safety Monitoring Board (DSMB) including three experts in clinical testing and/or renal function and one biostatistician will assess safety, including acute renal failure, when the study drug has been administered to 50 and 100 patients. The DSMB will recommend the study team to continue the study or not based on these safety data. A first meeting after 50 patients, in October 2015, and a second meeting in March 2016 after 100 patients were enrolled, resulted in the recommendation to continue the study without any changes in the protocol.

Specific safety considerations

The risks associated with a single 2.5 mg/kg intravenous dose of ciclosporin are considered small. Clinically relevant ciclosporin-associated side effects according to the Investigator Brochure (IB) for CicloMulsion are adverse allergic responses (anaphylactoid reactions) that may lead to anaphylactic shock, acute renal failure, hypertension or infections. These last three AEs are dose-dependent and usually occur during repeated administration.

Anaphylactoid reactions

Importantly, anaphylactoid reaction observed with the commercially available form of ciclosporin (Sandimmun) has been attributed to the presence of Kolliphor EL (Cremophor EL) in the product. In this study, a cremophor-free ciclosporin (CicloMulsion) and placebo will be used. However, this does not fully exclude the risk for allergic reactions to the study drug.

Renal failure

Calcineurin inhibitors such as ciclosporin are associated with induction of renal failure. The proposed mechanism for this is induction of vasoconstriction of the afferent arteriole by causing an imbalance between vasoconstricting47–49 and vasodilating50 ,51 agents. This results in an acute reversible52 ,53 impairment of renal function with reduction in glomerular filtration rate54 and tubular dysfunction.55 Renal failure as an AE is associated with long-term use and higher doses of ciclosporin than will be used in our study.

Induction of acute reversible impairment of renal failure as described above cannot be excluded in our study. However, we consider it as unlikely. Three clinical trials in a similar population administered ciclosporin in the same dose, but different formulations, as in our study.45 ,56 ,57 No renal side effects were reported. A recent large trial administering CicloMulsion in the same dose and in a similar population as in our study did not find any renal side effects.58 These four studies excluded patients with severe renal impairment and the CicloMulsion IB reports known creatinine clearance <30 mL/min/1.73/m2 as a contraindication. Preoperative impairment of renal function is a strong risk factor for developing AKI after cardiac surgery.42 To investigate if patients with the lowest renal function might also benefit from ciclosporin preoperatively, we include patients with eGFR 15–90 mL/min/1.73/m2, that is, with worse renal function. In addition, we also obtain safety data on these patients.


Blood pressure is included as a safety parameter.


We follow infection parameters such as CRP, leucocytes and body temperature daily. The leg wound infection rate is assessed on D4 using a standardised method.59 Also, we study immunological parameters as secondary variables on an exploratory base.

Dissemination plan

Results are going to be presented in a peer-reviewed medical journal. The study is investigator initiated and the protocol is written without any external influence. The study group will have the freedom to publish results regardless of the outcome. A clinical study report including study results will also be sent to the Swedish MPA and to the Regional Ethical Review Board. Archived study documents and source data will be filed at least 10 years after the study report has been finalised and submitted to the MPA. All processed data will be stored on the hospitals data servers with the same level of security as patient electronical records.


Ciclosporin to Protect Renal function In Cardiac Surgery (CiPRICS) is designed to investigate if ciclosporin has renoprotective effects if administered as a single intravenous injection before start of ECC in CABG surgery. It is, to the best of our knowledge, the first study to test this hypothesis and therefore a proof-of-concept study.

We consider the experimental studies where ciclosporin is demonstrated to inhibit a cyclophilin D-associated opening of the mPTP and thus protect the mitochondria from deterioration after ischaemia–reperfusion injury as a good scientific rationale to raise and test our hypothesis.

Earlier clinical trials administering ciclosporin in the same way, to a similar population, have not reported a difference in creatinine between active study drug and placebo. However, renal function was only evaluated through P-creatinine and only as a safety variable. Although it is by far the most used biomarker for AKI, we consider P-creatinine to have limitations. Consensus does not exist in the literature on how renal function could best be evaluated. In our opinion, cystatin C has a higher precision and less confounding factors than creatinine,60 ,61 especially in the milder degrees of renal impairment. Other interesting biomarkers are U-TIMP-2 and U-IGFBP762 and also U-albumin/creatinine. We believe that the probability for finding a true renal effect is higher with these biomarkers as compared with fluctuations in P-creatinine only.

Since existing impairment in renal function already preoperatively is a considerable risk factor for developing AKI after cardiac surgery, we only include patients with eGFR 15–90 mL/min/1.73/m2. Thus, we believe that we study the population most prone to postoperative AKI. Since we do not know if it is the patients with the worst or the best renal function who might benefit the most from pretreatment with ciclosporin, if the hypothesis should be confirmed, we will stratify the patients into groups with milder (eGFR 60–90 mL/min/1.73/m2) and more severe (eGFR 15–59 mL/min/1.73/m2) impairment of renal function preoperatively. Based on the prevalence in patients with CABG, it can be difficult to enrol a sufficient number of patients in the lower eGFR range. We therefore predefined that this group should enclose ∼50 patients. Importantly, we also needed to evaluate the eGFR 15–59 mL/min/1.73/m2 group from a safety perspective, which also motivated a stratification. The primary objective, however, is to examine the whole study population with eGFR 15–90 mL/min/1.73/m2. In summary, we consider our design to reflect a good balance between safety and efficacy where the proof-of-concept can be tested.

As presented above, the cellular mechanisms for our hypothesis concerning ciclosporin's renoprotective effect and its documented nephrotoxic effects are different. Approximately 580 patients have been exposed to ciclosporin in an identical dose as in our study.45 ,56–58 The safety data collected in these four clinical studies in cardiac patients is of high quality and renal side effects are reported equally in placebo and ciclosporin-treated patients. However, CicloMulsion was used only in the CIRCUS study, the largest of the studies.58 Other formulations were used in the other three. Taken together, the safety profile in our study is, in our view, reasonable.

Possible weaknesses derive from the fact that we cannot include all patients suitable for enrolment because of an uneven distribution in the operation programme over the weekdays. Thus, on some days when several patients are available for enrolment, there could be a bias introduced in the selection of patients. Also, the eGFR stratification might infer a bias in the sense that a larger proportion of the study population might be shifted towards higher stages of chronic kidney disease compared with the general CABG population. Moreover, if the hypothesis is true, we do not know the optimal dose for ciclosporin to exert its renoprotective effect. The choice of 2.5 mg/kg is considered to give the best efficacy combined with good safety. However, the measurement of ciclosporin concentration in blood during the day of operation will help us to evaluate this issue.

In summary, the CiPRICS study investigates the possibility of ciclosporin as a novel preventive pharmacological treatment to attenuate the AKI associated with CABG surgery. The study aims to be completed during the second half of 2016.


View Abstract


  • Contributors The authors are exclusively responsible for the design and conduct of this study. All study analyses, the drafting and editing of the final manuscript, and its final contents are planned to include all authors. PE is the co-principal investigator and was involved in writing of study protocol, writing and review of study protocol article, conducting of study including enrolment of patients, collection of study data. EG is the investigator and was involved in writing of study protocol, writing and review of study protocol article, conducting of study including enrolment of patients, collection of study data, performing analysis for immunological exploratory parameters. AD, BB, CM, AE, SN and AM are investigators and were involved in writing of study protocol, writing and review of study protocol article, conducting of study including enrolment of patients, collection of study data. MJH, EE and LA are investigators and were involved in writing of study protocol, writing and review of study protocol article. SJ was involved in providing laboratory and performing analysis for immunological exploratory parameters, writing of study protocol, writing and review of study protocol article. HB is the sponsor and primary investigator and was involved in writing of study protocol, writing and review of study protocol article, conducting of study including enrolment of patients, collection of study data.

  • Funding This work was supported by the Swedish Heart-Lung foundation grant number 86601. NeuroVive Pharmaceutical AB, Lund, Sweden, provided the study treatment CicloMulsion and its placebo together with unrestricted research grants covering costs for the research nurses.

  • Competing interests PE has received lecture fees from Orion Pharma AB. MJH received employment by and shareholder of NeuroVive Pharmaceutical AB, Lund, Sweden. EE received employment by and shareholder of NeuroVive Pharmaceutical AB, Lund, Sweden.

  • Ethics approval The research project was approved by the Regional Ethical Review Board, Lund (18–12–2014) and the Swedish Medical Products Agency (19–02–2015).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.